Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: A randomized controlled study

AIDS

Volumn 21, Issue 16, 2007, Pages 2217-2222

  Parienti, Jean Jacques ^a,b,c,g   Massari, Véronique ^a,b   Reliquet, Véronique ^d   Chaillot, Fabien ^c   Le Moal, Gwenaël ^e   Arvieux, Cédric ^f   Vabret, Astrid ^c   Verdon, Renaud ^c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CHU CÔTE DE NACRE   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Adherence; Nevirapine; Once daily; Twice daily

Indexed keywords

NEVIRAPINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; ELECTRONIC MEDICAL RECORD; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERVENTION STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VALIDATION PROCESS; VIRUS INHIBITION;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEVIRAPINE; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 37349020276     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282eff388     Document Type: Article

References (27)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
2. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Robertson M, Zolopa AR, Moss A. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
3. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316.
4. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence-resistance relationships for protease and nonnucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
5. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
6. Vickers AJ. Parametric versus nonparametric statistics in the analysis of randomized trials with nonnormally distributed data. BMC Med Res Methodol 2005; 5:35.
7. Liu H, Golin CE, Miller LG, Hays RD, Beck K, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977.
8. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6:185-190.
9. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
10. Molina JM, Journot V, Morand-Joubert L, Yeni P, Rozenbaum W, Rancinan C, et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005; 191:830-839.
11. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16:2342-2344.
12. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-396.
13. Mackie NE, Fidler S, Tamm N, Clarke JR, Back D, Weber JN, Taylor GP. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5:180-184.
14. Arnedo-Valero M, Garcia F, Gil C, Guila T, Fumero E, Castro P, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41:883-890.
15. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21:169-178.
16. Dargere S, Parienti JJ, Verdon R. Treatment resistance after sequential interruption of a nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS 2007; 21:879-880.
17. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
18. Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004; 189: 1974-1982.
19. Hogg RS, Heath K, Bangsberg D, Yip B, Press N,O'Shaughnessy MV, Montaner JS. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
20. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
21. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
22. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
23. Negredo E, Molto J, Munoz-Moreno JA, Pedrol E, Ribera E, Viciana P, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther 2004; 9:335-342.
24. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, Suter F. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163.
25. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
26. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
27. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36:808-816.